[Two novel fixed formulations of nucleoside analogues (tenofovir-emtricitabine, and abacavir-lamivudine). Prospective, open study on clinical practice and therapeutic perspectives, in patients naïve and in subjects pre-treated with antiretrovirals].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Manfredi R;Manfredi R; Calza L
  • Source:
    Recenti progressi in medicina [Recenti Prog Med] 2008 Oct; Vol. 99 (10), pp. 492-501.
  • Publication Type:
    Clinical Trial; English Abstract; Journal Article
  • Language:
    Italian
  • Additional Information
    • Transliterated Title:
      Due nuove formulazioni fisse di analoghi nucleosidici (tenofovir-emtricitabina ed abacavir-lamivudina). Studio prospettico in aperto sul potenziale terapeutico in pazienti naïve ed in soggetti pretrattati con antiretrovirali.
    • Source:
      Publisher: Il Pensiero Scientifico Editore Country of Publication: Italy NLM ID: 0401271 Publication Model: Print Cited Medium: Print ISSN: 0034-1193 (Print) Linking ISSN: 00341193 NLM ISO Abbreviation: Recenti Prog Med Subsets: MEDLINE
    • Publication Information:
      Original Publication: Roma : Il Pensiero Scientifico Editore
    • Subject Terms:
      Adenine/*analogs & derivatives ; Antiviral Agents/*administration & dosage ; Deoxycytidine/*analogs & derivatives ; HIV Infections/*drug therapy ; Lamivudine/*therapeutic use ; Organophosphonates/*administration & dosage ; Reverse Transcriptase Inhibitors/*administration & dosage; Adenine/administration & dosage ; Adult ; Deoxycytidine/administration & dosage ; Dideoxynucleosides ; Drug Combinations ; Emtricitabine ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Tenofovir
    • Abstract:
      The introduction of novel, fixed nucleoside-nucleotide reverse transcriptase inhibitor (NRTI) combinations (tenofovir-emtricitabine, and abacavir-lamivudine), expanded the spectrum of available formulations and increased patient's adherence. A prospective survey of the open-label use of these two fixed combinations was performed in 158 patients belonging to our single-centre cohort of over 1,000 HIV-infected subjects enrolled in the last 18 months, and followed for at least 12 months. During the last 18 months, 95 consecutive, evaluable patients (60.1%) received for the first time tenofovir-emtricitabine, or abacavir-lamivudine (63 patients, 39.9%), and were followed for at least 12 months. A major role seems to be played by tenofovir-emtricitabine in first-line treatments (preferably among "compact" regimens based on efavirenz), while the proportionally increased abacavir-lamivudine prescription to pre-treated patients is mostly attributable to the different genetic barrier of abacavir (often associated with boosted protease inhibitors, in this last patient group). The present availability to two more fixed NRTI combinations favored by their single pill, once-daily administration encourages randomized, controlled "head to head" studies in both first-line and experienced patients, in order to better exploit and target their therapeutic potential.
    • Accession Number:
      0 (Antiviral Agents)
      0 (Dideoxynucleosides)
      0 (Drug Combinations)
      0 (Organophosphonates)
      0 (Reverse Transcriptase Inhibitors)
      0 (abacavir, lamivudine drug combination)
      0W860991D6 (Deoxycytidine)
      2T8Q726O95 (Lamivudine)
      99YXE507IL (Tenofovir)
      G70B4ETF4S (Emtricitabine)
      JAC85A2161 (Adenine)
    • Publication Date:
      Date Created: 20081202 Date Completed: 20090305 Latest Revision: 20151119
    • Publication Date:
      20221213
    • Accession Number:
      19040127